PPT-DTG-Based Regimens Are Active in INI-Naive Patients With a

Jim Demarest 1 Mark Underwood 2 Marty St Clair 2 David Dorey 3 Steve Almond 3 Robert Cuffe 4 Dannae Brown 5 Garrett Nichols 6 1 ViiV Healthcare Global RampD Research Triangle Park NC USA . Anthony Yezzi. Georgia Institute of Technology. Snakes: Active Contour Models. Snakes or Active Contours pose the segmentation as an energy minimization problem.. Kass, Witkins & Terzopoulos.. Initialization. KGMU. Top five states in India which have highest number of leprosy cases. State 2009-10 2010-11 2011-12 2012-13. Uttar Pradesh 27,473 25,509 24,627 24,222. Out With the Old, In With the New. Current Standard of Care. NEUTRINO and FISSION. . SOF + RBV ± pegIFN for Treatment-naive Patients. NEUTRINO and FISSION. . SOF + RBV ± pegIFN for Treatment-naive Patients. Rates of VTE* in Newly Diagnosed MM . Treatment. No Prophylaxis. Any Prophylaxis. ASA. Warfarin. 1-1.25 mg/d. Prophylactic LMWH. Therapeutic Anticoagulation. T alone . (95% CI) . 1.3 . (0.4–2.7) . KGMU. Top five states in India which have highest number of leprosy cases. State 2009-10 2010-11 2011-12 2012-13. Uttar Pradesh 27,473 25,509 24,627 24,222. Learning Objectives. Understand when to switch to a second-line regimen. Know preferred second-line regimens for adults (including pregnant and breastfeeding women), adolescents, and children. Describe common drug resistance mutations and how they influence choosing a second-line regimen. -occlusive disease (VOD). Haematopoietic stem cell transplantation. Pathophysiology of VOD. Diagnosis of VOD. Assessment and management . of VOD. VOD case studies. Contents. Module 1: Haematopoietic stem cell transplantation. . Case. 47-Year-Old . Man With Asymptomatic HIV Infection. Case (cont). Initial Clinical Presentation. Laboratory Results. HepaScore. ®. A Composite Biomarker Panel for Liver Fibrosis. Hepatic Steatosis in Patients With HIV/HCV Coinfection. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Drew Lambert, . PharmD. lambertd@husson.edu. Husson University School of Pharmacy. 1. PollEverywhere. - Text . DREWLAMBERT221 to 22333 to join. You . can respond at . PollEv.com/drewlambert221. I have no conflicts of interest.. www.hivguidelines.org. Purpose of . This Guideline. Provide a clear and concise roadmap for clinicians to follow in choosing from among several equally efficacious ART regimens based on individual patient characteristics and preferences.. tenofovir. . alafenamide. (TAF) in virologically suppressed (VS) persons. Kayla M. Natali, PharmD, BCIDP, AAHIVP. 1,. , James Fallon. 2. , Dante Puntiel. 3. , Marina Metrus. 3. , . Ammer. Al-Dairi. Anastasiya Nestsiarovich, MD, PhD. Postdoctoral Fellow. University of New . Mexico Health Sciences Center. Department of Internal . Medicine. Center . for Global . Health. September 16, 2019. Research team:. double-blind, placebo-controlled study with open-label extension. Atul Deodhar, MD. Oregon Health & Science University. Portland, OR, USA. Key message. Upadacitinib – a JAK1 inhibitor – showed sustained and consistent efficacy over 1 year in AS patients..